Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd ( announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevn (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use....